In accordance with the government's goal of localization in health and medicine; Maxicells initiated its investments in 2018, aiming to become the leading biological drug provider and manufacturer both in Turkey and throughout the world.
Maxicells has set out to produce specific blood products that have already been manufactured by a few centers in the world, however not yet been produced in Turkey. Maxicells, which has already prepared its investment plans to build the very first plant of Turkey to produce specific blood products, has undertaken the procurement of 4 main plasma products (factor 8, factor 9, immunoglobulin and albumin) as finished products within the 5-year period until the beginning of domestic production. Maxicells production facility is currently being built on 150 decares of land in Silivri district with a total investment of 600 million Euro and aims to become one of the leading blood plasma production centers not only in Turkey but also in the world.
The company, in collaboration with the Turkish Red Crescent, further aims to domestically produce plasma products from domestic plasma and to consequently ensure that Turkey becomes a self-sufficient country in terms of producing blood and blood products.
In this direction, the company has invested to start up the first biological laboratory for blood products in Turkey with the aim to produce drugs used in treatment of hemophilia, certain infections, rheumatoid arthritis, leukemia and other immune system diseases and deliver them to patients.
Maxicells, which has initiated a major investment in order to manufacture blood products, continues its collaboration with the leading technology companies in the world in addition to BIOTEST AG in terms of production technology.
Maxicells engages in innovative and sustainable approaches in all its business on its destination to become the leading biological drug manufacturer both in Turkey and throughout the world.